StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX - Free Report) from a sell rating to a hold rating in a research report report published on Tuesday.
Other analysts also recently issued reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. Finally, The Goldman Sachs Group lifted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $40.67.
Read Our Latest Research Report on TG Therapeutics
TG Therapeutics Stock Up 9.2 %
Shares of TGTX stock traded up $3.25 during trading hours on Tuesday, reaching $38.44. 4,137,139 shares of the company's stock were exchanged, compared to its average volume of 2,560,778. TG Therapeutics has a 1 year low of $12.93 and a 1 year high of $38.58. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market cap of $5.98 billion, a PE ratio of -384.36 and a beta of 2.30. The stock's fifty day moving average price is $30.95 and its two-hundred day moving average price is $28.43.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Research analysts predict that TG Therapeutics will post 0.08 EPS for the current year.
Insider Buying and Selling at TG Therapeutics
In other news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 10.50% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On TG Therapeutics
A number of large investors have recently bought and sold shares of the business. Arizona State Retirement System grew its holdings in TG Therapeutics by 0.9% in the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. lifted its position in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after acquiring an additional 463 shares during the period. Private Advisor Group LLC increased its holdings in TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock worth $337,000 after acquiring an additional 542 shares in the last quarter. Finally, Brookstone Capital Management raised its position in TG Therapeutics by 3.7% during the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock worth $527,000 after acquiring an additional 624 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.
About TG Therapeutics
(
Get Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Further Reading
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
